---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2025-12-26T10:22:57.581357'
end_time: '2025-12-26T10:32:10.787115'
duration_seconds: 553.21
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: ARSB
  gene_symbol: ARSB
  uniprot_accession: P15848
  protein_description: 'RecName: Full=Arylsulfatase B; Short=ASB; EC=3.1.6.12; AltName:
    Full=N-acetylgalactosamine-4-sulfatase; Short=G4S; Flags: Precursor;'
  gene_info: Name=ARSB;
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the sulfatase family. .
  protein_domains: Alkaline_phosphatase_core_sf. (IPR017850); ARSB. (IPR047115); Sulfatase_CS.
    (IPR024607); Sulfatase_N. (IPR000917); Sulfatase (PF00884)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 25
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P15848
- **Protein Description:** RecName: Full=Arylsulfatase B; Short=ASB; EC=3.1.6.12; AltName: Full=N-acetylgalactosamine-4-sulfatase; Short=G4S; Flags: Precursor;
- **Gene Information:** Name=ARSB;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the sulfatase family. .
- **Key Domains:** Alkaline_phosphatase_core_sf. (IPR017850); ARSB. (IPR047115); Sulfatase_CS. (IPR024607); Sulfatase_N. (IPR000917); Sulfatase (PF00884)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "ARSB" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'ARSB' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **ARSB** (gene ID: ARSB, UniProt: P15848) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P15848
- **Protein Description:** RecName: Full=Arylsulfatase B; Short=ASB; EC=3.1.6.12; AltName: Full=N-acetylgalactosamine-4-sulfatase; Short=G4S; Flags: Precursor;
- **Gene Information:** Name=ARSB;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the sulfatase family. .
- **Key Domains:** Alkaline_phosphatase_core_sf. (IPR017850); ARSB. (IPR047115); Sulfatase_CS. (IPR024607); Sulfatase_N. (IPR000917); Sulfatase (PF00884)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "ARSB" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'ARSB' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **ARSB** (gene ID: ARSB, UniProt: P15848) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Comprehensive Research Report: Human ARSB (UniProt P15848)

Executive summary

- Verified identity: ARSB encodes human arylsulfatase B (N‑acetylgalactosamine‑4‑sulfatase), a lysosomal sulfatase (EC 3.1.6.12) that removes the 4‑O‑sulfate from N‑acetylgalactosamine‑4‑sulfate residues at the non‑reducing ends of dermatan sulfate and chondroitin‑4‑sulfate. Catalysis requires a Cα‑formylglycine (FGly) cofactor generated by SUMF1. ARSB is synthesized with a signal peptide, N‑glycosylated, mannose‑6‑phosphate (M6P)–tagged, and trafficked via the M6P receptor to lysosomes, with reported extra‑lysosomal localization. Deficiency causes mucopolysaccharidosis VI (MPS VI, Maroteaux–Lamy). (tobacman2022profoundimpactof pages 1-2, tobacman2022profoundimpactof pages 29-30, tobacman2022profoundimpactof pages 2-5, stapletonbradley2020screeningandtreatments pages 206-211)
- Clinical implementations: Enzyme replacement therapy (ERT) with galsulfase (Naglazyme) is approved for MPS VI, supported by 2024 consensus recommendations and real‑world pharmacovigilance (2005–2023 FAERS). Access and multidisciplinary care remain critical system needs. (alsayed2024consensusbasedexpertrecommendations pages 9-11, alsayed2024consensusbasedexpertrecommendations pages 2-4, alsayed2024consensusbasedexpertrecommendations pages 4-5, li2024realworldpharmacovigilanceanalysis pages 1-2)

Key concepts and definitions (current understanding)

- Molecular identity and family: ARSB is a human lysosomal sulfatase in the broader alkaline phosphatase/sulfatase superfamily; the ARSB gene maps to 5q14.1. The enzyme was historically identified as the ARSB activity deficient in MPS VI. (Tobacman & Bhattacharyya 2022; DOI: https://doi.org/10.3390/ijms232113146) (tobacman2022profoundimpactof pages 1-2, tobacman2022profoundimpactof pages 29-30)
- Enzymatic reaction and specificity: ARSB catalyzes hydrolysis of the 4‑O‑sulfate at the non‑reducing end of N‑acetylgalactosamine‑4‑sulfate, acting on dermatan sulfate and chondroitin‑4‑sulfate in glycosaminoglycan (GAG) catabolism; activity is often assayed with nitrocatechol sulfate/4‑methylumbelliferyl sulfate. (tobacman2022profoundimpactof pages 1-2, tobacman2022profoundimpactof pages 2-5)
- Catalytic cofactor and activation: The catalytic cysteine (e.g., Cys91) is post‑translationally converted to Cα‑formylglycine (FGly) by the formylglycine‑generating enzyme encoded by SUMF1, a requirement shared across sulfatases and central to the pathobiology of multiple sulfatase deficiency. (tobacman2022profoundimpactof pages 1-2, tobacman2022profoundimpactof pages 29-30)
- Maturation and targeting: ARSB is synthesized with an N‑terminal signal peptide, undergoes N‑glycosylation and M6P tagging, and is delivered to lysosomes via M6P receptors, where proteolytic maturation yields the active enzyme. Mechanistic background on M6P trafficking and sulfatase maturation is established in the lysosome literature. (Stapleton‑Bradley dissertation 2020; DOI: https://doi.org/10.58088/kwzy-g903) (stapletonbradley2020screeningandtreatments pages 206-211)
- Localization: Canonically lysosomal; extra‑lysosomal localization at cell surface and nucleus has been reported in human epithelia and other tissues, suggesting roles beyond classical lysosomal catabolism. (tobacman2022profoundimpactof pages 2-5, tobacman2022profoundimpactof pages 23-25, tobacman2022profoundimpactof pages 30-31)
- Disease definition: ARSB deficiency causes MPS VI (Maroteaux–Lamy), a lysosomal storage disorder with dermatan/chondroitin‑4‑sulfate accumulation; SUMF1 defects cause multiple sulfatase deficiency that secondarily impairs ARSB activation. (tobacman2022profoundimpactof pages 16-17, tobacman2022profoundimpactof pages 27-29)

> Human ARSB (arylsulfatase B; EC 3.1.6.12) is a member of the sulfatase family that functions as an exo‑sulfohydrolase.
> It catalyzes hydrolysis of the 4‑O‑sulfate at the non‑reducing terminus of N‑acetylgalactosamine‑4‑sulfate residues in dermatan sulfate and chondroitin‑4‑sulfate.
> Catalysis requires a Cα‑formylglycine at the active‑site cysteine, generated post‑translationally by the formylglycine‑generating enzyme encoded by SUMF1 (FGE).
> ARSB is synthesized with an N‑terminal signal peptide, undergoes N‑linked glycosylation and mannose‑6‑phosphate modification, and is trafficked via M6P receptors to lysosomes where it is proteolytically matured.
> While its canonical residence and function are lysosomal in glycosaminoglycan catabolism, extra‑lysosomal localization at the cell surface and in nuclei has been reported.
> Loss of ARSB activity causes accumulation of dermatan sulfate and chondroitin‑4‑sulfate, producing mucopolysaccharidosis type VI (Maroteaux–Lamy syndrome), and defective SUMF1 can create a multiple sulfatase deficiency context that impairs ARSB activation.
> Because ARSB‑mediated desulfation alters glycosaminoglycan structure, ARSB activity influences extracellular‑matrix interactions and cell signaling beyond classical lysosomal storage pathology.


*Blockquote: Concise, citable summary of ARSB identity, reaction, maturation/trafficking, localization, pathway role, and disease relevance for use in the full report (sources: Tobacman et al. 2022 review and lysosomal trafficking background) (tobacman2022profoundimpactof pages 1-2, stapletonbradley2020screeningandtreatments pages 206-211).*

Recent developments and latest research (emphasis 2023–2024)

- Consensus recommendations for MPS VI (2024): A national Delphi‑style expert panel (Saudi Arabia) issued management recommendations for MPS VI, emphasizing immediate initiation of ERT (galsulfase) upon diagnosis, establishment of multidisciplinary care teams, individualized follow‑up, and system‑level actions (centers of excellence, national registries, reimbursement programs). Limitations of current ERT (e.g., weekly infusions, limited impact on ocular/skeletal/established cardiac disease) and the need for home‑infusion pathways are highlighted (Orphanet J Rare Dis, Jul 2024; https://doi.org/10.1186/s13023-024-03237-3). (alsayed2024consensusbasedexpertrecommendations pages 9-11, alsayed2024consensusbasedexpertrecommendations pages 2-4, alsayed2024consensusbasedexpertrecommendations pages 4-5)
- Real‑world safety of galsulfase (2005–2023 FAERS, published 2024): A pharmacovigilance analysis of 20,281,876 FAERS reports identified 3,195 galsulfase‑associated AEs; signal detection across four algorithms found 27 affected organ systems (notably respiratory and infections). Median AE onset was 1,471 days with over half within five years. Newly signaled urologic AEs (e.g., membranous glomerulonephritis, nephritic syndrome) underscore the need for continued surveillance (Frontiers in Pharmacology, Aug 2024; https://doi.org/10.3389/fphar.2024.1420126). (li2024realworldpharmacovigilanceanalysis pages 1-2)
- Burden and quality of life (China, 2019 survey; published 2024): In a cross‑sectional survey (n=180; includes MPS VI cases) diagnostic delay averaged 9.42 months; only 6.67% were diagnosed at the first visit; patients averaged 6.31 visits and 4.3 hospitals before diagnosis. Direct medical costs during the diagnostic period averaged ¥81,086.72 (63.75% of total). Only 32.78% had received specific treatments; HRQoL (PedsQL/SF‑36) was significantly lower than population norms, with household income, treatment, and subtype associated with HRQoL (Orphanet J Rare Dis, Sep 2024; https://doi.org/10.1186/s13023-024-03333-4). (kang2024healthserviceutilization pages 1-2, kang2024healthserviceutilization pages 6-8)
- Mechanistic breadth (2022–2024): Reviews and preclinical reports continue to detail ARSB’s regulation of cell‑signaling via changes in chondroitin‑4‑sulfate sulfation and binding partners, plus extra‑lysosomal localizations in human tissues; these support expanding biological roles beyond classical storage pathology. (tobacman2022profoundimpactof pages 1-2, tobacman2022profoundimpactof pages 23-25, tobacman2022profoundimpactof pages 30-31)

Current applications and real‑world implementations

- Enzyme replacement therapy (ERT): Galsulfase is the approved recombinant human ARSB for MPS VI. Clinical consensus emphasizes early initiation and structured, multidisciplinary follow‑up, with selective use of home‑infusion programs to improve adherence and access (Orphanet J Rare Dis 2024; https://doi.org/10.1186/s13023-024-03237-3). (alsayed2024consensusbasedexpertrecommendations pages 2-4, alsayed2024consensusbasedexpertrecommendations pages 4-5)
- Pharmacovigilance in practice: FAERS data through Q4 2023 provide real‑world AE profiles and onset timing for galsulfase—supporting risk communication, monitoring plans, and hypothesis generation for rare, off‑label, or long‑latency events (Frontiers in Pharmacology 2024; https://doi.org/10.3389/fphar.2024.1420126). (li2024realworldpharmacovigilanceanalysis pages 1-2)
- Health systems and access: National‑level recommendations and burden studies identify the need for centers of excellence, registries, and reimbursement mechanisms to reduce diagnostic delay and improve equitable ERT access. China’s national rare‑disease network (since 2019) illustrates system‑level responses to these needs (Orphanet J Rare Dis 2024; https://doi.org/10.1186/s13023-024-03333-4; Orphanet J Rare Dis 2024; https://doi.org/10.1186/s13023-024-03237-3). (kang2024healthserviceutilization pages 1-2, kang2024healthserviceutilization pages 6-8, alsayed2024consensusbasedexpertrecommendations pages 9-11)

Expert opinions and authoritative analysis

- National expert consensus: The 2024 Saudi consensus provides structured recommendations for MPS VI care delivery, including early ERT, multidisciplinary management, and system‑level reforms, reflecting authoritative, context‑adapted clinical guidance (Orphanet J Rare Dis 2024; https://doi.org/10.1186/s13023-024-03237-3). (alsayed2024consensusbasedexpertrecommendations pages 9-11, alsayed2024consensusbasedexpertrecommendations pages 2-4, alsayed2024consensusbasedexpertrecommendations pages 4-5)
- Mechanistic reviews: ARSB’s core biochemistry, SUMF1‑dependent activation, and expanding physiological roles are reviewed with synthesis across human and model data, supporting the canonical lysosomal catabolic function and extra‑lysosomal activities (IJMS 2022; https://doi.org/10.3390/ijms232113146). (tobacman2022profoundimpactof pages 1-2, tobacman2022profoundimpactof pages 29-30, tobacman2022profoundimpactof pages 2-5)

Relevant statistics and data (recent studies)

- Galsulfase AE profile (FAERS 2005–2023): 3,195 galsulfase‑associated AE reports; 27 organ systems implicated; median AE onset 1,471 days; over half within five years; new urologic signals observed—publication Aug 2024 (Frontiers in Pharmacology; https://doi.org/10.3389/fphar.2024.1420126). (li2024realworldpharmacovigilanceanalysis pages 1-2)
- Diagnostic journey and costs (China, published 2024): Mean diagnostic delay 9.42 months; 6.67% diagnosed at first visit; average 6.31 visits/4.3 hospitals before diagnosis; mean direct medical costs during diagnosis ¥81,086.72 (63.75% of total); only 32.78% received specific treatments; HRQoL significantly below norms (Orphanet J Rare Dis; https://doi.org/10.1186/s13023-024-03333-4). (kang2024healthserviceutilization pages 1-2, kang2024healthserviceutilization pages 6-8)

Detailed functional annotation of ARSB

- Reaction and pathway: ARSB is an exo‑sulfohydrolase that removes terminal 4‑O‑sulfate from GalNAc‑4‑sulfate residues in dermatan sulfate/chondroitin‑4‑sulfate, a late step in lysosomal GAG breakdown. Deficiency elevates C4S/DS storage, driving MPS VI pathology in cartilage, connective tissues, and viscera. (tobacman2022profoundimpactof pages 1-2, tobacman2022profoundimpactof pages 2-5, tobacman2022profoundimpactof pages 16-17)
- Subcellular localization: Predominantly lysosomal via M6P‑guided trafficking; extra‑lysosomal localizations (cell surface, nucleus) have been reported in human epithelium, liver, and other tissues, suggesting signaling effects through altered GAG sulfation in microdomains. (tobacman2022profoundimpactof pages 2-5, tobacman2022profoundimpactof pages 23-25, tobacman2022profoundimpactof pages 30-31)
- Maturation and cofactor biology: SUMF1‑dependent FGly generation is essential for catalysis; defects in SUMF1 produce multiple sulfatase deficiency with broad loss of sulfatase activities including ARSB. M6P receptor–mediated sorting and proteolytic maturation complete activation and lysosomal deployment. (tobacman2022profoundimpactof pages 29-30, stapletonbradley2020screeningandtreatments pages 206-211)

Clinical relevance and therapy landscape

- MPS VI (Maroteaux–Lamy): ARSB mutations cause MPS VI; disease burden includes progressive skeletal dysplasia, cardiopulmonary disease, ophthalmic involvement, and systemic manifestations. ERT with galsulfase improves endurance, pulmonary function, and global symptoms, though limitations exist for skeletal/ocular/established cardiac disease. Early initiation and coordinated multidisciplinary care are advised. (Orphanet J Rare Dis 2024; https://doi.org/10.1186/s13023-024-03237-3) (alsayed2024consensusbasedexpertrecommendations pages 2-4, alsayed2024consensusbasedexpertrecommendations pages 4-5)
- Safety and monitoring: Long‑term pharmacovigilance indicates multi‑system AEs and emerging signals, reinforcing the need for structured monitoring programs and registry‑based follow‑up (Frontiers in Pharmacology 2024; https://doi.org/10.3389/fphar.2024.1420126). (li2024realworldpharmacovigilanceanalysis pages 1-2)
- Health systems perspective: Real‑world data emphasize substantial diagnostic delays, financial burden, and under‑utilization of specific therapies, motivating national networks, reimbursement schemes, and home‑infusion options to improve outcomes and equity (Orphanet J Rare Dis 2024; https://doi.org/10.1186/s13023-024-03333-4; https://doi.org/10.1186/s13023-024-03237-3). (kang2024healthserviceutilization pages 1-2, kang2024healthserviceutilization pages 6-8, alsayed2024consensusbasedexpertrecommendations pages 9-11)

Verification of gene/protein identity and ambiguity check

- The ARSB symbol corresponds to human arylsulfatase B (N‑acetylgalactosamine‑4‑sulfatase; UniProt P15848), a lysosomal sulfatase. Literature cited above consistently studies human ARSB and the human disease MPS VI; no conflicting use of the symbol for a different gene/protein in another organism was found in the evidence set used here. Domain/family assignment (sulfatase) and required FGly modification align with sulfatase family characteristics. (tobacman2022profoundimpactof pages 1-2, tobacman2022profoundimpactof pages 29-30, tobacman2022profoundimpactof pages 2-5)

References and source metadata

- Tobacman JK, Bhattacharyya S. Profound impact of decline in N‑acetylgalactosamine‑4‑sulfatase (Arylsulfatase B) on molecular pathophysiology and human diseases. International Journal of Molecular Sciences. Published Oct 2022. URL: https://doi.org/10.3390/ijms232113146 (tobacman2022profoundimpactof pages 1-2, tobacman2022profoundimpactof pages 29-30, tobacman2022profoundimpactof pages 23-25, tobacman2022profoundimpactof pages 30-31, tobacman2022profoundimpactof pages 16-17, tobacman2022profoundimpactof pages 27-29, tobacman2022profoundimpactof pages 2-5)
- AlSayed M, et al. Consensus‑based expert recommendations on the management of MPS IVa and VI in Saudi Arabia. Orphanet Journal of Rare Diseases. Published Jul 2024. URL: https://doi.org/10.1186/s13023-024-03237-3 (alsayed2024consensusbasedexpertrecommendations pages 9-11, alsayed2024consensusbasedexpertrecommendations pages 2-4, alsayed2024consensusbasedexpertrecommendations pages 4-5)
- Li S, et al. Real‑world pharmacovigilance analysis of galsulfase (FAERS 2005–2023). Frontiers in Pharmacology. Published Aug 2024. URL: https://doi.org/10.3389/fphar.2024.1420126 (li2024realworldpharmacovigilanceanalysis pages 1-2)
- Kang Q, et al. Health service utilization, economic burden and quality of life of patients with mucopolysaccharidosis in China. Orphanet Journal of Rare Diseases. Published Sep 2024. URL: https://doi.org/10.1186/s13023-024-03333-4 (kang2024healthserviceutilization pages 6-8, kang2024healthserviceutilization pages 1-2)
- Stapleton‑Bradley M. Screening and treatments for the mucopolysaccharidoses (dissertation). University of Delaware. Published 2020. URL: https://doi.org/10.58088/kwzy-g903 (stapletonbradley2020screeningandtreatments pages 206-211)

Limitations

- Some mechanistic background on lysosomal targeting and M6P trafficking is derived from established literature summarized in a dissertation source in the evidence set; readers should refer to primary lysosome/M6P receptor reviews for additional mechanistic detail. (stapletonbradley2020screeningandtreatments pages 206-211)


References

1. (tobacman2022profoundimpactof pages 1-2): Joanne K Tobacman and Sumit Bhattacharyya. Profound impact of decline in n-acetylgalactosamine-4-sulfatase (arylsulfatase b) on molecular pathophysiology and human diseases. International Journal of Molecular Sciences, Oct 2022. URL: https://doi.org/10.3390/ijms232113146, doi:10.3390/ijms232113146. This article has 23 citations and is from a poor quality or predatory journal.

2. (tobacman2022profoundimpactof pages 29-30): Joanne K Tobacman and Sumit Bhattacharyya. Profound impact of decline in n-acetylgalactosamine-4-sulfatase (arylsulfatase b) on molecular pathophysiology and human diseases. International Journal of Molecular Sciences, Oct 2022. URL: https://doi.org/10.3390/ijms232113146, doi:10.3390/ijms232113146. This article has 23 citations and is from a poor quality or predatory journal.

3. (tobacman2022profoundimpactof pages 2-5): Joanne K Tobacman and Sumit Bhattacharyya. Profound impact of decline in n-acetylgalactosamine-4-sulfatase (arylsulfatase b) on molecular pathophysiology and human diseases. International Journal of Molecular Sciences, Oct 2022. URL: https://doi.org/10.3390/ijms232113146, doi:10.3390/ijms232113146. This article has 23 citations and is from a poor quality or predatory journal.

4. (stapletonbradley2020screeningandtreatments pages 206-211): Molly Stapleton-Bradley. Screening and treatments for the mucopolysaccharidoses. Dissertation, 2020. URL: https://doi.org/10.58088/kwzy-g903, doi:10.58088/kwzy-g903. This article has 0 citations.

5. (alsayed2024consensusbasedexpertrecommendations pages 9-11): Moeenaldeen AlSayed, Dia Arafa, Huda Al-Khawajha, Manal Afqi, Nouriya Al-Sanna’a, Rawda Sunbul, and Maha Faden. Consensus-based expert recommendations on the management of mps iva and vi in saudi arabia. Orphanet Journal of Rare Diseases, Jul 2024. URL: https://doi.org/10.1186/s13023-024-03237-3, doi:10.1186/s13023-024-03237-3. This article has 2 citations and is from a peer-reviewed journal.

6. (alsayed2024consensusbasedexpertrecommendations pages 2-4): Moeenaldeen AlSayed, Dia Arafa, Huda Al-Khawajha, Manal Afqi, Nouriya Al-Sanna’a, Rawda Sunbul, and Maha Faden. Consensus-based expert recommendations on the management of mps iva and vi in saudi arabia. Orphanet Journal of Rare Diseases, Jul 2024. URL: https://doi.org/10.1186/s13023-024-03237-3, doi:10.1186/s13023-024-03237-3. This article has 2 citations and is from a peer-reviewed journal.

7. (alsayed2024consensusbasedexpertrecommendations pages 4-5): Moeenaldeen AlSayed, Dia Arafa, Huda Al-Khawajha, Manal Afqi, Nouriya Al-Sanna’a, Rawda Sunbul, and Maha Faden. Consensus-based expert recommendations on the management of mps iva and vi in saudi arabia. Orphanet Journal of Rare Diseases, Jul 2024. URL: https://doi.org/10.1186/s13023-024-03237-3, doi:10.1186/s13023-024-03237-3. This article has 2 citations and is from a peer-reviewed journal.

8. (li2024realworldpharmacovigilanceanalysis pages 1-2): Shangze Li, Runcheng Huang, Yuanyuan Meng, Yijia Liu, Jiao Qian, Junjie Zou, and Jun Yang. Real-world pharmacovigilance analysis of galsulfase: a study based on the fda adverse event reporting system (faers) database. Frontiers in Pharmacology, Aug 2024. URL: https://doi.org/10.3389/fphar.2024.1420126, doi:10.3389/fphar.2024.1420126. This article has 2 citations and is from a poor quality or predatory journal.

9. (tobacman2022profoundimpactof pages 23-25): Joanne K Tobacman and Sumit Bhattacharyya. Profound impact of decline in n-acetylgalactosamine-4-sulfatase (arylsulfatase b) on molecular pathophysiology and human diseases. International Journal of Molecular Sciences, Oct 2022. URL: https://doi.org/10.3390/ijms232113146, doi:10.3390/ijms232113146. This article has 23 citations and is from a poor quality or predatory journal.

10. (tobacman2022profoundimpactof pages 30-31): Joanne K Tobacman and Sumit Bhattacharyya. Profound impact of decline in n-acetylgalactosamine-4-sulfatase (arylsulfatase b) on molecular pathophysiology and human diseases. International Journal of Molecular Sciences, Oct 2022. URL: https://doi.org/10.3390/ijms232113146, doi:10.3390/ijms232113146. This article has 23 citations and is from a poor quality or predatory journal.

11. (tobacman2022profoundimpactof pages 16-17): Joanne K Tobacman and Sumit Bhattacharyya. Profound impact of decline in n-acetylgalactosamine-4-sulfatase (arylsulfatase b) on molecular pathophysiology and human diseases. International Journal of Molecular Sciences, Oct 2022. URL: https://doi.org/10.3390/ijms232113146, doi:10.3390/ijms232113146. This article has 23 citations and is from a poor quality or predatory journal.

12. (tobacman2022profoundimpactof pages 27-29): Joanne K Tobacman and Sumit Bhattacharyya. Profound impact of decline in n-acetylgalactosamine-4-sulfatase (arylsulfatase b) on molecular pathophysiology and human diseases. International Journal of Molecular Sciences, Oct 2022. URL: https://doi.org/10.3390/ijms232113146, doi:10.3390/ijms232113146. This article has 23 citations and is from a poor quality or predatory journal.

13. (kang2024healthserviceutilization pages 1-2): Qi Kang, Yuhang Fang, Yan Yang, Dingguo Li, Lin Zheng, Xinyi Chen, Xiaowen Tu, and Chunlin Jin. Health service utilization, economic burden and quality of life of patients with mucopolysaccharidosis in china. Orphanet Journal of Rare Diseases, Sep 2024. URL: https://doi.org/10.1186/s13023-024-03333-4, doi:10.1186/s13023-024-03333-4. This article has 9 citations and is from a peer-reviewed journal.

14. (kang2024healthserviceutilization pages 6-8): Qi Kang, Yuhang Fang, Yan Yang, Dingguo Li, Lin Zheng, Xinyi Chen, Xiaowen Tu, and Chunlin Jin. Health service utilization, economic burden and quality of life of patients with mucopolysaccharidosis in china. Orphanet Journal of Rare Diseases, Sep 2024. URL: https://doi.org/10.1186/s13023-024-03333-4, doi:10.1186/s13023-024-03333-4. This article has 9 citations and is from a peer-reviewed journal.

## Citations

1. stapletonbradley2020screeningandtreatments pages 206-211
2. li2024realworldpharmacovigilanceanalysis pages 1-2
3. tobacman2022profoundimpactof pages 1-2
4. tobacman2022profoundimpactof pages 29-30
5. tobacman2022profoundimpactof pages 2-5
6. alsayed2024consensusbasedexpertrecommendations pages 9-11
7. alsayed2024consensusbasedexpertrecommendations pages 2-4
8. alsayed2024consensusbasedexpertrecommendations pages 4-5
9. tobacman2022profoundimpactof pages 23-25
10. tobacman2022profoundimpactof pages 30-31
11. tobacman2022profoundimpactof pages 16-17
12. tobacman2022profoundimpactof pages 27-29
13. kang2024healthserviceutilization pages 1-2
14. kang2024healthserviceutilization pages 6-8
15. https://doi.org/10.3390/ijms232113146
16. https://doi.org/10.58088/kwzy-g903
17. https://doi.org/10.1186/s13023-024-03237-3
18. https://doi.org/10.3389/fphar.2024.1420126
19. https://doi.org/10.1186/s13023-024-03333-4
20. https://doi.org/10.1186/s13023-024-03333-4;
21. https://doi.org/10.3390/ijms232113146,
22. https://doi.org/10.58088/kwzy-g903,
23. https://doi.org/10.1186/s13023-024-03237-3,
24. https://doi.org/10.3389/fphar.2024.1420126,
25. https://doi.org/10.1186/s13023-024-03333-4,